Pakistan abolishes some medicine tariffs

30 July 2006

Pakistan's new SRO 567 (1) 2006 abolishes the import duty on all medicines for cancer, kidney dialysis and transplant, vaccines and interferon, as well as and other mediciations for hepatitis.

In addition, import of all vaccines/anti-sera, cardiovascular drugs, blood bags CPDA1; medicines for HIV/AIDS and thalassemia have also been exempted from import duty. Duty on imports of eye drops and medicinal ointments have been reduced.

The government has also excluded certain items including raw materials for the pharmaceutical industry from the concessionary SRO 567(1) 2006 for withdrawal of the rate of customs duty notified in the budget. It will now levy customs duty on imports of these, as specified in the Pakistan Customs Tariff.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.